Upcoming Events and Webinars

Dr. Rakesh Nagarajan

Dr. Rakesh Nagarajan
CEO, PierianDx

Dr. Eric Loo

Dr. Eric Loo
Assistant Professor, Dartmouth-Hitchcock

Bringing NGS Testing In-House

May 2, 7:00-7:50 AM

Is insourcing NGS testing worth it?

Dartmouth-Hitchcock has experienced nearly 40% savings by bringing NGS testing in-house. A recent AMP study using non-small cell lung cancer as an example cites $2.7 million in anticipated savings.

In-house NGS testing is the foundation of any modern precision medicine program. It can have a profound effect on patient care. And, as these examples show, a strong business case can be made.

How have Dartmouth-Hitchcock and other progressive institutions been so successful despite myriad challenges?

Join us for a webinar on May 31st at 12pm ET as Eric Loo, MD (Dartmouth-Hitchcock) and Rakesh Nagarajan, MD, PhD (PierianDx) explore answers to this question and more.

In this webinar you will learn:

  • How recent precision medicine trends are driving strong market growth for clinical NGS and other complex molecular testing.
  • How to make a strong business case for in-house NGS testing.
  • Challenges your institution is likely to face by insourcing.
  • Blueprints for overcoming these challenges, including reimbursement.

View Recording

Past Webinars

PierianDx to Exhibit at ACMG 2018

April 10-14

PierianDx will highlight germline features of its genomics technology platform at the American College of Medical Genetics and Genomics (ACMG) annual meeting April 10-14 in Charlotte, North Carolina.

Representatives from PierianDx will be on hand in Booth 1203 demonstrating the Clinical Genomics WorkSpace (CGW), the industry’s leading integrated workspace for genomic analytics, classification, interpretation and reporting.

CGW germline testing features include phenotype-based prioritization of variants and rapid classification of variants following ACMG guidelines. PierianDx’s support for germline testing also includes Clinical Microarray (CMA), commonly used in the germline setting to evaluate complex development disorders.

PierianDx complements its germline technology with a range of support services. The company’s interpretation services involves clinical and scientific teams leveraging CGW’s patented knowledgebase to provide highly scalable and reliable clinical interpretations for inherited diseases. Interpretations by PierianDx variant scientists and medical directors are combined with machine learning within the knowledgebase comprised of million of biomedical finding to produce the most clinically actionable insight available for customers.

If you would like to learn more about PierianDx or CGW, please schedule a meeting during ACMG.

Dr. Rakesh Nagarajan

Dr. Rakesh Nagarajan
CEO, PierianDx

PierianDx Hosts Expert Customer Panel Discussion Regarding Debated CMS National Coverage Decision on NGS Testing

February 22, 2018

PierianDx CEO, Dr. Rakesh Nagarajan, and Medical Director, Dr. Shalini Verma, recently posted their perspectives on the CMS website (See Comments). On February 22 at 2 pm CST, Dr. Nagarajan and Dr. Verma will facilitate a roundtable discussion among representatives from NorthShore University Health System, Moffitt Cancer Center, UVA Health System, the Medical College of Georgia at Augusta University, and the University of Vermont Health System.

The panel discussion will focus on how the proposal to limit the coverage to only FDA approved NGS tests with companion diagnostic indications could impose restrictive criteria for coverage with development, making explicit a policy of non-coverage for NGS tests if the test does not meet criteria listed in the proposed NCD. For academic centers, leading cancer institutions, and essential community cancer centers that have CLIA-certified laboratories providing validated laboratory developed NGS-based tests, the policy would supersede existing local coverage policies for most of those tests and limit Medicare beneficiaries’ access to a single test.

Featuring Speakers from:

  • Ravindra Kolhe, MD, PhD, Director, Georgia Esoteric & Molecular Laboratory at Augusta University
  • Karen L. Kaul, MD, PhD, Chairman of the Department of Pathology, NorthShore University Health System
  • Theresa Ann Boyle, MD, PhD, Molecular Genetic Pathologist at Moffitt Cancer Center
  • Mani S. Mahadevan, M.D., Professor of Pathology Medical Director of Molecular Diagnostics Laboratory at UVA Health System
  • Nikoletta Sidiropoulos, M.D., Director of the University of Vermont Health System Genomics Medicine Laboratory

 

Watch Recorded Webinar

Precision Oncology Roundtable: Ask the Experts about NGS-based Tumor Profiling

October 12, 2017

Featuring Speakers from:

Dartmouth-Hitchcock
Augusta University
Moffitt Cancer Center

This webinar was an interactive roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers.

Our expert panel — Gregory Tsongalis from Dartmouth-Hitchcock, Anthony Magliocco from Moffitt Cancer Center, Ravindra Kolhe from Augusta University, and Rakesh Nagarajan from PierianDx — will specifically discuss their experiences with Illumina’s TruSight Tumor 170 targeted cancer assay.

The TST170 next-generation sequencing-based panel targets single nucleotide variants, indels, gene amplifications, gene fusions, splice variants, mRNA expression, and mRNA isoform detection found in 170 cancer-related genes and also calculates metrics such as tumor mutation burden and determines evidence for microsatellite instability.

Our panelists will discuss the design of the assay, data analytics, and reasons behind their selection of the TST170 assay, and will share details of how it is being utilized within their organizations.

Watch Recorded Webinar

Dr. Rakesh Nagarajan

Dr. Rakesh Nagarajan
CEO, PierianDx

Clinical Genomicist Workspace (CGW): Accelerate Your NGS Testing with an End-to-End Integrated Workspace

September 28, 2017

PierianDx accelerates precision medicine by offering one space to handle a range of genomic testing, from somatic to constitutional, from small panels to whole exome or genome. During this webinar, PierianDx Chief Biomedical Informatics Officer Dr. Rakesh Nagarajan will provide an overview of CGW and illustrate how the industry leading platform seamlessly manages genomic data and workflow for each case, from variant analysis and classification to interpretation, reporting and final sign out. Nagarajan will discuss:

  • An overview of CGW key features and functions
  • How PierianDx’s knowledgebase helps to deliver clinically actionable results by leveraging millions of biomedical findings across multiple databases to analyze and classify each detected variant
  • Examples of actionable clinical reports, both somatic and constitutional
  • Customer case studies and how CGW has accelerated NGS testing programs, streamlined lab efficiencies and ultimately improved patient care

Watch Recorded Webinar

Dr. Rakesh Nagarajan

Dr. Rakesh Nagarajan
CEO, PierianDx

Building a Best-in-Class Precision Medicine Program: The Moffitt Cancer Center Story

September 14, 2017

Building a world-class precision medicine program takes the right mix of innovative leadership, advanced technology, clinical acumen, and strategic partnerships. During this webinar, Dr. Anthony Magliocco, the Chair of Anatomic Pathology at Moffitt Cancer Center, will share the Moffitt success story – from its pioneering inception to being one of only 47 Comprehensive Cancer Centers as designated by the National Cancer Institute.
Dr. Magliocco will discuss:

  • Key variables that played an important part in Moffitt Cancer Center’s evolution.
  • The role of the state-of-the-art Morsani Molecular Diagnostics Laboratory played in that evolution
  • Pathways to success, unexpected barriers, and an in-depth review of what steps were taken to ensure that the patient comes first
  • A blueprint for other clinical labs seeking to accelerate precision medicine and NGS testing

Watch Recorded Webinar

Dr. Rakesh Nagarajan

Dr. Rakesh Nagarajan
CEO, PierianDx

Taking Your NGS Testing Program to the Next Level with Enhanced Validation and Interpretation Services

July 13, 2017 at 11:00am CST

The success of any precision medicine program involves the right combination of personnel and technology. PierianDx’s Clinical Genomicist Workspace (CGW) has been the technology platform of choice for clinical labs to seamlessly manage their genomic data and workflow from variant analysis and classification to interpretation, reporting and final sign out. However, the right strategy and clinical resources at the validation and interpretation stages are just as important to that success. During this webinar, PierianDx Chief Bioinformatics Officer Rakesh Nagarajan will discuss ways clinical labs can improve validation and interpretation approaches to enhance report actionability, relevance and throughput. Specifically, Nagarajan will discuss:

  • Guidelines for improved test validation covering a range of examples
  • Various validation reports, covering a range of different assays
  • Understanding the different roles of automated interpretation and clinical interpretation utilizing genomic scientists and medical directors
  • Case studies of customers who have enhanced their clinical lab capability with PierianDx validation and interpretation services

Watch Recorded Webinar

Dr. Nikoletta Sidiropoulos

Dr. Nikoletta Sidiropoulos

Accelerating Your NGS Testing Program: Examples and Case Studies

On March 9th, Clinical Genomicist Workspace user and Partner Sharing Network contributor, Dr. Nikoletta Sidiropoulos from University of Vermont Medical Center hosted a webinar with PierianDx exploring various ways clinical labs have established or expanded their NGS testing programs by implementing improved workflow and clinical integration into their organization. Dr. Sidiropoulos shared her experiences and lessons learned as she works to evolve the university’s precision medicine program. Specific examples were shared on how to improve clinical lab workflow, starting with DNA or RNA samples and ending with a report of relevant variants to assist in clinical decision-making. By the end of this webinar, participants will have some real-world examples of how to accelerate their own personalized medicine initiatives from clinical experts in the field.

Watch Recorded Webinar

NGS Roundtable: Ask the Experts about the Future of Clinical NGS Testing

This interactive roundtable discusses established and emerging regulatory, scientific, and medical topics related to next-generation sequencing in the clinical setting. An expert panel of leading pathologists, medical geneticists, and researchers will address genomic testing advances in two thematic areas: 1) scientific and clinical trends in reporting, and 2) clinical lab operations and quality management.

Topics covered by the expert panel include the importance of proficiency testing, both from the regulatory and quality perspective, and technical and clinical advances in using NGS to predict effective immunotherapy and determine tumor mutation load.

Watch Recorded Webinar

Recent News

PierianDx Expands to Australia with Addition of Anatomical Pathology PathWest Laboratory Medicine

PierianDx Expands to Australia with Addition of Anatomical Pathology PathWest Laboratory Medicine

June 11, 2018
PierianDx, the leading clinical genomics technology company that enables precision medicine, announced today that the Department of Anatomical Pathology PathWest Laboratory Medicine will use the company’s Clinical Genomics WorkSpace™ (CGW) platform,
Read More
PierianDx Hires Healthcare IT, Analytics Pioneer as CEO

PierianDx Hires Healthcare IT, Analytics Pioneer as CEO

May 23, 2018
MAY 24, 2018 -- ST. LOUIS -- PierianDx, the leader in clinical genomics solutions, announced today that it has appointed Michael L. Sanderson as Chief Executive Officer and Director of the Board. In his new role, Sanderson will execute on the
Read More
PierianDx Partners with ScienceVision to Bring Robust Precision Medicine Support to Southeast Asia

PierianDx Partners with ScienceVision to Bring Robust Precision Medicine Support to Southeast Asia

May 13, 2018
MAY 14, 2018 -- ST. LOUIS -- PierianDx, the leading clinical genomics technology company that enables precision medicine, announced today that it has executed a distribution agreement with ScienceVision, a leading provider of end-to-end genomic
Read More
University of Alabama takes a Dogged Approach to Precision Medicine

University of Alabama takes a Dogged Approach to Precision Medicine

April 19, 2018
In the U.S. alone, there are nearly 700,000 people living with a primary brain tumor. And each year, there are nearly 70,000 new diagnoses and 17,000 deaths. [1]  With over 120 different types of tumors and a tricky blood-brain barrier to permeate,
Read More